시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 체외 암 진단 시장 보고서(2025년)
In Vitro Cancer Diagnostics Global Market Report 2025
상품코드 : 1877786
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,718,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,710,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,703,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

체외 암 진단 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2024년 106억 8,000만 달러로 평가되었고, 2025년에는 114억 9,000만 달러에 달하고, CAGR 7.5%로 성장할 전망입니다. 지난 몇 년간의 성장은 암 이환율의 상승, 조기 암 발견에 관한 환자 의식의 높아짐, 분자진단 기술의 보급 확대, 의료 인프라에 대한 투자 확대, 암 진단을 위한 바이오마커 발견 조사에 대한 주목의 고조에 기인하는 것으로 예측됩니다.

체외 암 진단 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 155억 4,000만 달러에 달하고, CAGR은 7.8%를 나타낼 전망입니다. 예측 기간 동안의 성장은 종양학에서 개인화된 의료 수요 증가, 포인트 오브 케어 암 진단 수요 증가, 저침습 검사법에 대한 인지도 향상, 생명공학 및 진단 스타트업 기업에 대한 투자 증가, 비용 효율적인 진단 솔루션에 대한 수요 증가에 의해 견인됩니다. 예측 기간의 주요 동향에는 액체 생검 기술의 발전, 인공지능과의 통합, 미세 유체 플랫폼 혁신, 디지털 병리 시스템 개발, 유전체 데이터 분석의 진전이 포함됩니다.

액체 생검 기술의 채택 확대는 향후 수년간 체외 암 진단 시장의 성장을 가속할 것으로 예측됩니다. 액체 생검 기술이란 혈액, 소변, 타액 등의 체액 중에 존재하는 순환 종양 DNA, 순환 종양 세포, 엑소좀 등의 바이오마커를 검출·분석하고, 특히 암에서의 질환의 존재, 진행, 치료 반응을 모니터링하는 저침습적 진단 수법을 말합니다. 혈액이나 기타 체액으로부터 순환 종양 DNA나 순환 종양 세포를 분리·분석하는 기술의 진보에 의해 액체 생검 기술의 활용이 확대되고 있습니다. 액체 생검 기술의 급속한 보급에 따라 암 검출 및 치료 지침을 위한 비침습적이고 실시간 분자 프로파일링 툴의 도입이 진행되고 있는 가운데 체외 암 진단 솔루션에 대한 수요가 높아지고 있습니다. 예를 들어, 2025년 5월에는 영국 공적의료제도인 NHS 잉글랜드에 따르면 영국에서 새롭게 도입되는 액체 생검 혈액 검사는 연간 최대 1만 5,000명의 폐암 의심 환자와 5,000명의 진행성 유방암 여성 환자에게 혜택을 가져올 것으로 전망되고 있습니다. 2025년 초 도입 시 약 2,200명의 검사 대상자에서 2028년까지 연간 추정 2만명 규모로 확대될 전망입니다. 따라서 액체 생검 기술의 채용 확대는 체외 암 진단 시장의 성장을 가속하고 있습니다.

체외 암 진단 시장에서 사업을 전개하는 주요 기업은 환자의 치료 성과 향상과 맞춤형 의료의 추진을 목적으로 AI 구동형 암 진단 기술의 개발에 주력하고 있습니다. AI 구동형 암 진단에서는 환자 검체, 이미지, 유전자 검사에서 얻은 의료 데이터와 분자 데이터를 인공지능으로 분석하여 암의 매우 정확한 검출, 진단, 예측을 실현합니다. 예를 들어, 2024년 9월에는 스위스에 본사를 둔 제약회사 로슈사가 디지털 병리학 오픈 환경을 도입했습니다. 이것은 Roche와 여러 타사 개발자들이 첨단 AI 기반 이미지 분석 도구를 안전하게 통합하는 공동 플랫폼입니다. 이 플랫폼을 통해 병리학자들은 Roche의 'Navify Digital Pathology' 기업 소프트웨어 내에서 혁신적인 알고리즘에 액세스할 수 있어 진단 정확도와 워크플로우 효율성이 향상됩니다. 협동과 데이터 공유를 촉진함으로써, 암 진단·조사의 혁신을 가속하고, 정밀의료를 지원함과 동시에, 보다 효과적인 표적 치료를 가능하게 해, 첨단적인 디지털 병리 솔루션에의 세계적인 액세스를 확대합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

In vitro cancer diagnostics refers to laboratory-based tests conducted on samples such as blood, tissue, or other body fluids to detect, monitor, or evaluate cancer outside the human body. These diagnostics employ techniques like molecular assays, biomarker analysis, and genetic profiling to identify the presence or progression of cancer. They support early detection, accurate diagnosis, and informed treatment planning for patients.

The key product types in in vitro cancer diagnostics include kits, instruments, reagents, software, and consumables. Kits are ready-to-use sets of reagents and materials designed for diagnostic testing, enabling biomarker detection, supporting disease monitoring, and assisting in treatment evaluation. Technologies used include polymerase chain reaction (PCR), next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), immunohistochemistry, and others. These diagnostics are applied across multiple cancer types, including breast cancer, lung cancer, colorectal cancer, and prostate cancer, and serve end users such as hospitals, diagnostic laboratories, research institutes, home care settings, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers' margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The in vitro cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides in vitro cancer diagnostics market statistics, including in vitro cancer diagnostics industry global market size, regional shares, competitors with a in vitro cancer diagnostics market share, detailed in vitro cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the in vitro cancer diagnostics industry. This in vitro cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The in vitro cancer diagnostics market size has grown strongly in recent years. It will grow from $10.68 billion in 2024 to $11.49 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth observed during the historical period can be attributed to the rising prevalence of cancer, heightened awareness among patients regarding early cancer detection, increased adoption of molecular diagnostic techniques, expanded investments in healthcare infrastructure, and a growing focus on research in biomarker discovery for cancer diagnostics.

The in vitro cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $15.54 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth during the forecast period is driven by the increasing demand for personalized medicine in oncology, rising demand for point-of-care cancer diagnostics, growing awareness of minimally invasive testing methods, increasing investment in biotech and diagnostic startups, and rising need for cost-effective diagnostic solutions. Primary trends in the forecast period include advancements in liquid biopsy technology, integration with artificial intelligence, innovation in microfluidics platforms, development of digital pathology systems, and progress in genomic data analysis.

The rising adoption of liquid biopsy technologies is expected to enhance the growth of the in vitro cancer diagnostics market in the coming years. Liquid biopsy technologies refer to minimally invasive diagnostic methods that detect and analyze biomarkers such as circulating tumor DNA, circulating tumor cells, or exosomes present in body fluids like blood, urine, or saliva to monitor disease presence, progression, or response to treatment, particularly in cancer. The use of liquid biopsy technologies is increasing due to advancements in isolating and analyzing circulating tumor DNA and circulating tumor cells from blood and other body fluids. In vitro cancer diagnostic solutions are experiencing higher demand as the rapid adoption of liquid biopsy technologies encourages companies to implement non invasive and real time molecular profiling tools for cancer detection and treatment guidance. For example, in May 2025, according to NHS England, a UK based public healthcare system, the new liquid biopsy blood test rollout in the UK is expected to benefit up to 15,000 patients with suspected lung cancer and 5,000 women with advanced breast cancer annually, expanding from about 2,200 patients tested during the early 2025 rollout to an estimated 20,000 patients per year by 2028. Therefore, the rising adoption of liquid biopsy technologies is enhancing the growth of the in vitro cancer diagnostics market.

Leading companies operating in the in vitro cancer diagnostics market are emphasizing the development of AI-driven cancer diagnostics to improve patient outcomes and advance personalized healthcare. AI-driven cancer diagnostics involve the use of artificial intelligence to analyze medical and molecular data from patient samples, imaging, or genetic tests, enabling highly accurate detection, diagnosis, and prediction of cancer. For instance, in September 2024, Roche, a Switzerland-based pharmaceutical company, introduced the Digital Pathology Open Environment, a collaborative platform that securely integrates advanced AI-based image analysis tools from Roche and multiple third-party developers. The platform allows pathologists to access innovative algorithms within Roche's Navify Digital Pathology enterprise software, enhancing diagnostic precision and workflow efficiency. By fostering collaboration and data sharing, the platform accelerates innovation in cancer diagnostics and research, supports precision medicine, and enables more effective targeted treatments, expanding global access to advanced digital pathology solutions.

In February 2024, Veracyte Inc., a US-based molecular diagnostics company, acquired C2i Genomics, Inc. for an undisclosed amount. Through this acquisition, Veracyte aims to expand its presence across the cancer care continuum by incorporating AI-driven whole-genome minimal residual disease testing to enhance treatment monitoring and detect disease recurrence. C2i Genomics Inc. is a US-based biotechnology company that provides in vitro cancer diagnostics.

Major players operating in the in vitro cancer diagnostics market are F. Hoffmann-La Roche Ltd, Danaher Corporation, Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers AG, Illumina Inc, Hologic Inc, Qiagen N.V, Bio-Rad Laboratories Inc, Agilent Technologies, Becton, Dickinson and Company (BD), Sysmex Corporation, LabCorp Holding Corp., Guardant Health, Quest Diagnostics, Exact Sciences, Myriad Genetics Inc, Natera Inc., NeoGenomics Laboratories, NanoString Technologies Inc, Caris Life Sciences, Transasia Bio-Medicals Ltd, Autobio Diagnostics Co Ltd, QuidelOrtho Corporation, Cancer Diagnostics Inc, Predicine Inc, Strata Oncology, Biocept Inc, Lucence Diagnostics

North America was the largest region in the in vitro cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vitro cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the in vitro cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The in vitro cancer diagnostics market consists of revenues earned by entities by providing services such as molecular diagnostic testing, biopsy and cytology analysis, companion diagnostic services, and next-generation sequencing (NGS) services. The market value includes the value of related goods sold by the service provider or included within the service offering. The in vitro cancer diagnostics market also includes sales of cancer biomarker kits, molecular diagnostic assays, flow cytometry kits, tissue-based diagnostic kits, and genomic testing panels. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

In Vitro Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on in vitro cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for in vitro cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The in vitro cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. In Vitro Cancer Diagnostics Market Characteristics

3. In Vitro Cancer Diagnostics Market Trends And Strategies

4. In Vitro Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global In Vitro Cancer Diagnostics Growth Analysis And Strategic Analysis Framework

6. In Vitro Cancer Diagnostics Market Segmentation

7. In Vitro Cancer Diagnostics Market Regional And Country Analysis

8. Asia-Pacific In Vitro Cancer Diagnostics Market

9. China In Vitro Cancer Diagnostics Market

10. India In Vitro Cancer Diagnostics Market

11. Japan In Vitro Cancer Diagnostics Market

12. Australia In Vitro Cancer Diagnostics Market

13. Indonesia In Vitro Cancer Diagnostics Market

14. South Korea In Vitro Cancer Diagnostics Market

15. Western Europe In Vitro Cancer Diagnostics Market

16. UK In Vitro Cancer Diagnostics Market

17. Germany In Vitro Cancer Diagnostics Market

18. France In Vitro Cancer Diagnostics Market

19. Italy In Vitro Cancer Diagnostics Market

20. Spain In Vitro Cancer Diagnostics Market

21. Eastern Europe In Vitro Cancer Diagnostics Market

22. Russia In Vitro Cancer Diagnostics Market

23. North America In Vitro Cancer Diagnostics Market

24. USA In Vitro Cancer Diagnostics Market

25. Canada In Vitro Cancer Diagnostics Market

26. South America In Vitro Cancer Diagnostics Market

27. Brazil In Vitro Cancer Diagnostics Market

28. Middle East In Vitro Cancer Diagnostics Market

29. Africa In Vitro Cancer Diagnostics Market

30. In Vitro Cancer Diagnostics Market Competitive Landscape And Company Profiles

31. In Vitro Cancer Diagnostics Market Other Major And Innovative Companies

32. Global In Vitro Cancer Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The In Vitro Cancer Diagnostics Market

34. Recent Developments In The In Vitro Cancer Diagnostics Market

35. In Vitro Cancer Diagnostics Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기